Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Saved in:

Bibliographic Details
Main Authors:	Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-01-01
Series:	Dermatology and Therapy
Online Access:	https://doi.org/10.1007/s13555-024-01328-4
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
by: Richard B. Warren, et al.
Published: (2024-11-01)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
by: Susanne Hartz, et al.
Published: (2020-08-01)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Fan Bai, et al.
Published: (2019-01-01)

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
by: Diamant Thaçi, et al.
Published: (2025-02-01)

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
by: Diamant Thaçi, et al.
Published: (2025-05-01)

Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice
by: Lam J, et al.
Published: (2025-03-01)

The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
by: Chen-Yu Wu, et al.
Published: (2019-01-01)

High maneuvering target tracking ATPM-IMM algorithm
by: Hao ZENG, et al.
Published: (2022-07-01)

High maneuvering target tracking ATPM-IMM algorithm
by: Hao ZENG, et al.
Published: (2022-07-01)

Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01)

Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017-01-01)

UIMM-Tracker: IMM-Based with Uncertainty Detection for Video Satellite Infrared Small-Target Tracking
by: Yuanxin Huang, et al.
Published: (2025-06-01)

IMM4HT:an identification method of malicious mirror website for high-speed network traffic
by: Lei ZHANG, et al.
Published: (2019-07-01)

Microwave-dried black soldier fly larvae enhance growth, intestinal health, and humoral imm
by: Osfar Sjofjan, et al.
Published: (2025-07-01)

Granuloma Annulare in the Setting of Secukinumab
by: Matthew L. Clark, et al.
Published: (2018-01-01)

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease
by: Brian G. Feagan, et al.
Published: (2025-01-01)

Time-Varying Fault Diagnosis for Asynchronous Multisensor Systems Based on Augmented IMM and Strong Tracking Filtering
by: Yanyan Hu, et al.
Published: (2018-01-01)

IMM-H007 promotes hepatic cholesterol and triglyceride metabolism by activating AMPKα to attenuate hypercholesterolemia
by: Jiaqi Li, et al.
Published: (2025-08-01)

Hypopigmented mycosis fungoides-like eruption following ixekizumab treatment
by: Sarah Balboul, BA, et al.
Published: (2025-04-01)

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
by: Tania F. Cestari, et al.
Published: (2025-04-01)

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
by: Andrea D'Arino, et al.
Published: (2025-07-01)

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01)

Robust Tracking Method for Small and Weak Multiple Targets Under Dynamic Interference Based on Q-IMM-MHT
by: Ziqian Yang, et al.
Published: (2025-02-01)

Dissecting Cellulitis of the Scalp Successfully Treated with a Combination of Ixekizumab and Tofacitinib
by: Qiu M, et al.
Published: (2025-05-01)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
by: Qianying Yu, et al.
Published: (2022-01-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Secukinumab in refractory non-infectious anterior uveitis
by: Otto M. Olivas-Vergara, et al.
Published: (2025-02-01)

Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis
by: Diamant Thaçi, et al.
Published: (2025-12-01)

Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
by: A. M. Dadalova, et al.
Published: (2020-11-01)

Paradoxical Behçet’s Disease after Ixekizumab: A Case Report and Literature Review
by: Yue-Kang Ren, et al.
Published: (2025-01-01)

Risankizumab and Certolizumab Pegol Dual-Targeted Therapy for Crohn’s Disease and Axial Spondyloarthritis: A Case Report
by: Anouk Lehmann, et al.
Published: (2024-12-01)

Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy
by: Aciel Ahmed Shaheen, et al.
Published: (2021-01-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis
by: Xiao Y, et al.
Published: (2025-07-01)

Eczematoid paradoxical reaction in psoriasis patients following secukinumab
by: Heng Zhang, et al.
Published: (2025-04-01)

A Case of Granuloma Annulare Associated with Secukinumab Use
by: Lauren Bonomo, et al.
Published: (2017-01-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
by: Stefano Gentileschi, et al.
Published: (2020-01-01)